XK469, a synthetic quinoxaline phenoxypropionic acid derivative, has been found to have selective activity against a broad panel of solid tumors including several drug-resistant cell lines and has been approved for phase I clinical evaluation. Recent studies suggested that XK469 is a selective topoisomerase IIb inhibitor, but the mechanism of XK469-induced cell death remains unknown. Here we investigate the ability of XK469 to induce apoptosis of human cancer cells. In the human ovarian cancer cell line PA1, XK469 caused the release of cytochrome c, activation of caspases including caspases 9, 7 and 3, cleavage of PARP, and subsequently cell death. Moreover, Bcl2 and Bax were cleaved in XK469 treated cells. PA1 cells expressing the dominant negative-caspase 9 were less sensitive to XK469. Importantly, in these PA1 cells expressing DN-casp 9, the activation of caspases including caspases 3, 7 and 9, and cleavage of Bax and Bcl2 were inhibited, suggesting that the activation of the mitochondrial pathway is required for XK469-induced anticancer activity. These results indicate that the induction of apoptosis by XK469 may account for its anti-tumor activity and such activity is required for the activation of the mitochondrial pathway. Thus, our study de®nes a possible mechanism, at least in part, underlying XK469-induced anti-cancer activity.
Introduction
A major obstacle to cancer chemotherapy is the development of resistant cell populations following the relapse of an initially responsive malignancy. Such chemoresistance has motivated researchers to develop new drugs that are more ecacious and have less side eect. Recently, a new compound named XK469 was found to have selective cytotoxicity for murine solid tumors as compared to leukemias LoRusso et al., 1998) . XK469 is a synthetic quinoxaline phenoxypropionic acid derivative and an analog of the inactive herbicide Assure LoRusso et al., 1998) . In vitro, XK469 has selective cytotoxicity for solid tumors including colorectal and mammary adenocarcinoma cell lines, when compared to leukemia or normal epithelial cells . In vivo, XK469 is active against murine tumors including pancreatic ductal carcinoma, colon adenocarcinoma and mammary adenocarcinoma . Importantly, XK469 is highly active against multidrug-resistant tumors LoRusso et al., 1998) . Moreover, XK469 has low toxicity in comparison to other anticancer agents LoRusso et al., 1998) . Therefore, XK469 has been selected by the National Cancer Institute for clinical development. Despite its promising anticancer activity, the molecular targets and mechanism of action of XK469 are not clear. Recent studies reported that XK469 is a selective topoisomerase IIb poison (Gao et al., 1999; Snapka et al., 2001) , but the eect of this compound on apoptosis, the main signaling pathway for chemotherapeutics, remains to be determined.
Apoptosis is a genetically controlled mechanism essential for the maintenance of tissue homeostasis, proper development and elimination of unwanted cells. In mammalian cells, two major apoptosis pathways are proposed: the ®rst one involves signals transduced through death receptors; the second relies on a signal from the mitochondria (Cryns and Yuan, 1998) . Both pathways are involved in an ordered activation of a set of cysteine proteases called caspases (Alnemri et al., 1996) , which in turn cleave cellular substrates and result in the morphological and biochemical changes characteristic of apoptosis (Cryns and Yuan, 1998) . Although chemotherapeutic agents may induce apoptosis through the death receptor pathway, the mitochondrial pathway is indicated as the primary pathway in anticancer drug-mediated cell killing. In response to anticancer drug treatment, the mitochondria are damaged and cytochrome c is released into the cytosol where it associates with Apaf1 and procaspase 9 in the presence of dATP, leading to caspase 9 activation (Li et al., 1997) . The activated caspase 9 can cleave downstream caspases, such as caspases 3, 6 and 7, leading to cell death (Srinivasula et al., 1998) .
In this study, we investigated the mechanism of XK469-induced cell killing in human cancer cell lines. We found that XK469 eectively kills ovarian cancer cells through the induction of apoptosis. The induction of apoptosis by XK469 is mediated by the caspase cascade of the mitochondrial pathway because blockade of caspase 9 activation decreased XK469-mediated apoptosis and increased chemoresistance. Thus apoptosis through the mitochondrial pathway may contribute at least in part to XK469-induced anticancer activity.
Results

XK469 can effectively inhibit the growth of ovarian cancer cell lines through the induction of apoptosis
To determine the eects of XK469 on cancer cell growth, two human ovarian cancer cell lines PA1 and SKOV3 were treated with XK469 at 0, 10, 20, 40, 80, and 120 mg/ml for 24 h and growth inhibition was assessed. Figure 1a shows that XK469 can eectively inhibit cell growth in both lines. PA1 is more sensitive to XK469, in which IC 50 was 60 mg/ml, while IC 50 for SKOV3 was 80 mg/ml (Figure 1a ). To test whether XK469 kills cells by apoptosis, PA1 cells were treated with XK469 at 0, 10, 20, 40 and 80 mg/ml for 24 h and activation of caspase 3, a hallmark of apoptosis, was determined. As shown in Figure 1b , caspase 3 activity was increased in a dose-dependent manner. For example, there was a 2.2-fold increase in cells treated with XK469 at 20 mg/ml and 4.8-fold increase at 80 mg/ ml, as compared with untreated cells (Figure 1b) . These results suggest that XK469 can cause apoptosis of PA1 cells. Consistent with the activation of caspase 3, DNA fragmentation, another hallmark of apoptosis, was detected in XK469-treated cells but not in untreated control cells (Figure 1c ). In addition, we assessed nuclear morphology by staining with DAPI, and documented condensed chromatin and fragmented nuclei (Figure 1d ). Taken together, these results indicate that XK469 can cause apoptosis of PA1 cells.
XK469 activates the mitochondria-mediated caspase cascade
To determine whether XK469-induced apoptosis of PA1 cells involves the activation of a caspase cascade, PA1 cells were treated with XK469 at 0, 10, 20, 40 and 80 mg/ml for 24 h and total proteins were extracted, and activation of caspases was measured by Western blot analysis. Figure 2a shows that caspases 7 and 3 were cleaved when cells were treated with XK469 at 40 and 80 mg/ml, as opposed to untreated cells in which no such changes were observed. Subsequently, cleavage of PARP, a hallmark of apoptosis, and substrate of caspases 3 and 7, was detectable (Figure 2a ). Because the activation of caspases 3 and 7 can be activated by either caspase 8 via the death receptor pathway or caspase 9 via the mitochondrial pathway (Cryns and Yuan, 1998), we next asked which pathway was predominant in XK469-induced apoptosis in PA1 cells. As shown in Figure 2a , caspase 9 was cleaved in XK469-treated cells whereas cleavage of caspase 8 was not evident, suggesting that the mitochondrial pathway may play an important role in this caspase cascade. To further investigate the role of the mitochondrial pathway in XK469-induced apoptosis, we examined the release of cytochrome c. As shown in Figure 2b , the release of cytochrome c is detected in the cytoplasm of XK469-treated cells but not in that of untreated control cells. It has been shown that in response to some apoptotic stimuli, the mitochondria are damaged, and in turn release cytochrome c into the cytosol where it is associated with Apaf1 and procaspase 9 in the presence of ATP or dATP, leading to caspase 9 activation (Li et al., 1997) and the subsequent activation of caspases 3 and 7. Therefore, these results support the notion that XK469 kills PA1 cells at least in part through induction of apoptosis predominantly through the mitochondrial pathway.
XK469 induces cleavage of Bcl2 and Bax
Mitochondrial damage and subsequent cytochrome c release are regulated by members of the Bcl2 family (Kluck et al., 1997; Vander Heiden et al., 1997; Yang et al., 1997) . The ratio of proapoptotic members, such as Bcl2 and Bcl-X L , and anti-proapoptotic members, such as Bax, determines whether cells live or die (Korsmeyer, 1999) . Since cytochrome c is released into the cytosol in XK469-treated PA1 cells, we asked whether XK469 can cause alternation in the levels of Bcl2 family members. PA1 cells were treated with XK469 at 0, 10, 20, 40 and 80 mg/ml for 24 h and total protein was extracted to assess the levels of Bax, Bcl2 and Bcl-X L by Western blotting with speci®c antibodies. As shown in Figure 2c , Bcl2 was cleaved into a 21 kd fragment, a truncated Bcl2 with Bax-like proapoptotic activity (Cheng et al., 1997) , in cells treated with either 40 or 80 mg/ml of XK469, whereas XK469 did not aect the level of Bcl-X L protein (Figure 2c) . Furthermore, the proapoptotic Bax was cleaved following XK469 treatment (Figure 2c) , consistent with the notion that Bax can be cleaved during anticancer drug-induced apoptosis and such cleaved fragment of Bax can enhance its cell death function (Wood and Newcomb, 2000) . In addition, we found that cleavage of Bcl2 and Bax occurred at 24 h but not 12 h following XK469 treatment (Figure 2d ), suggesting that cleavage of Bcl2 and Bax is a late event. It has been shown that cleavage of Bax is able to translocate to the mitochondria where it promotes cytochrome c release and subsequent caspase activation (Hsu et al., 1997) . To determine whether XK469 can induce Bax translocation from the cytosol to the mitochondria, PA1 cells were left untreated or treated
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The role of caspase 9 in XK469-induced apoptosis Z Ding et al with XK469 (80 mg/ml) for 24 h and mitochondriaenriched fraction was isolated to assay the Bax protein level. As shown in Figure 2e , the Bax protein was detected in XK469-treated cells as opposed to untreated cells in which the Bax level was low, suggesting that Bax is translocated into the mitochondria. Taken together, our results show that XK469 is a potent inducer of apoptosis by generating a more potent form 
Dominant negative caspase 9 blocks XK469-induced caspase cascade
We showed that caspase 9 but not caspase 8 was activated in XK469 treated PA1 cells. To determine whether caspase 9 was required for XK469-induced apoptosis, the eect of XK469 was tested on PA1 cell stably expressing a dominant negative caspase 9. Consistent with the results in Figure 2a , cleavage of caspase 9, 7 and 3, but not caspase 8, and PARP was detected in PA1 vector control cells treated with 40 or 80 mg/ml XK469. In contrast, such changes were not detected in cells expressing DN-casp 9 (Figure 3a) , suggesting that blockade of caspase 9 activation by its dominant negative mutant is sucient to inhibit XK469-induced caspase activation and subsequent apoptosis. These results further indicate that XK469 induces apoptosis of PA1 cells primarily through the mitochondrial pathway.
The effects of XK469 on cleavage of Bcl2 and Bax in DN-casp 9 expressing cells
We have shown that XK469 treatment induces cleavage of Bax and Bcl2, which generates either a Bax-like proapoptotic Bcl2 (Cheng et al., 1997) or a more potent form of Bax (Wood and Newcomb, 2000) to promote cytochrome c release. Since overexpression of DN-casp 9 blocked XK469-induced caspase activation and apoptosis, it is possible that such overexpression blocks cleavage of Bcl2 and Bax, thereby abrogating the generation of potent cleaved proapoptotic forms of both Bax-like Bcl2 and Bax, leading to decreased XK469-induced apoptosis. To test this possibility, PA1 cells transfected with vector or DN-casp 9 were treated with various concentrations of XK469 and the cleavage of Bcl2, Bcl-X L and Bax were measured by Western blotting. As expected, XK469 did not aect the levels of Bcl-X L in either control or DN-casp 9 expressing cells (Figure 3b) . Consistent with the results obtained with the parental PA1 cells (Figure 2c ), Bcl2 and Bax were cleaved in the vector cells treated with XK469 at 40 mg/ ml or 80 mg/ml (Figure 3b ). In contrast, such changes were abrogated in cells expressing DN-casp 9 ( Figure  3b ). Therefore, our results demonstrate that the activation of caspase 9 is required for XK469-induced cleavage of Bcl2 and Bax, which may occur downstream of caspase 9. Since XK469-induced Bcl2 and Bax cleavage was blocked in DN-casp 9 expressing cells, we next asked whether overexpression of DN-casp 9 has an eect on cytochrome c release. As shown in Figure  3c , the levels of XK469-induced cytochrome c release were comparable in both vector and DN-casp 9 PA1 cells, suggesting that overexpression of DN-casp 9 is unable to block XK469-induced cytochrome c release in PA1 cells. Since overexpression of DN-casp 9 blocked caspase activation and subsequent apoptosis induced by XK469 (Figure 3a) , these DN-casp 9 expressing cells may be less sensitive to XK469-induced killing. To test this, PA1 cells expressing either vector or DN-casp 9 were treated with increasing concentrations of XK469 for 2 days and cell survival was measured. As shown in Figure 4a , control PA1 cells were very sensitive to XK469-induced killing, which was consistent with the results obtained with the parent PA1 cells (Figure 1a) . In contrast, sensitivity of PA1 cells expressing DN-casp 9 to XK469 was reduced by at least 50% (Figure 4a ). For example, surviving rates of XK469-treated vector cells at 10 mg/ml and 20 mg/ml XK469 were *30 and 20% respectively, compared with 60 and 45%, respectively, for cells expressing DN-casp 9 ( Figure  4a ). Thus, these results demonstrate that the blockade of caspase 9 activation can render PA1 cells resistant to XK469-induced cell killing. Consistent with the survival results, treatment of PA1 vector cells with XK469 at 80 mg/ml resulted in an increase in caspase 3 activity with a 4.5-fold increase over untreated cells, as compared with DN-casp 9 expressing cells in which same treatment resulted in only a 2.4-fold increase over untreated cells (Figure 4b ). Similar results were obtained with XK469 treatment at 20 and 40 mg/ml (Figure 4b ). Taken together, these results suggested that the activation of the mitochondrial apoptosis pathway is important for XK469-induced cell killing.
Discussion
XK469 was reported to be a selective topo IIb inhibitor (Gao et al., 1999) and a subsequent study suggested that it also inhibits topo I (Snapka et al., 2001) . Our previous study showed that XK469 can induce G2/M arrest in lung cancer cells (Ding et al., 2001) . In the present study, we demonstrated that XK469 is a potent inducer of apoptosis in the ovarian cancer cells. Treatment of PA1 cells with XK469 caused release of cytochrome c, activation of caspases including caspases 9, 7 and 3, and cleavage of PARP. Furthermore, XK469 induced cleavage of the Bcl2 family members Bax and Bcl2. Moreover, blockade of caspase 9 activation inhibited XK469-induced apoptosis and thereby increasing chemoresistance. Collectively, these ®ndings demonstrate that XK469 induces apoptosis of tumor cells through the mitochondrial pathway.
Apoptosis may be triggered by either the death receptor or mitochondrial pathway (Cryns and Green, 1998) . Although anticancer drugs can activate the death receptor pathway, a mitochondrial pathway is believed to play a major role in anticancer drug-mediated killing (Costantini et al., 2000) . In the mitochondrial pathway, release of cytochrome c is a critical event for triggering apoptosis because cytochrome c forms a complex with Apaf-1 and procaspase 9 in the cytoplasm and activates caspase 9, leading to the activation of caspases 3, 6 and 7 and induction of apoptosis (Adams and Cory, 1998; Gross et al., 1999) . We showed that XK469 induces release of cytochrome c into the cytosol, activation of caspases 9, 7 and 3, and cleavage of PARP, indicating an Figure 3 Overexpression of DN-casp 9 blocks XK469-induced caspase cascade. (a) The eects of DN-casp 9 expression on XK469-induced caspase activation. PA1 cells transfected with vector or DN-casp 9 were left untreated or treated with XK469 at 10, 20, 40 and 80 mg/ml for 24 h and total proteins were prepared for analysing the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP as described in Materials and methods. (b) Overexpression of DN-casp 9 abrogates cleavage of Bcl2 and Bax caused by XK469. PA1 cells transfected with vector or DN-casp 9 were left untreated or treated with XK469 as in (a) and total proteins were prepared for analysing cleavage of Bcl2, Bcl-X L and Bax as described in Materials and methods. (c) Overexpression of DN-casp 9 has no eects on XK469-induced cytochrome c release. PA1 cells transfected with vector or DNcasp 9 were left untreated or treated with XK469 at 80 mg/ml for 24 h and cytosol fractions were prepared for detecting cytochrome c by Western blot analysis
The role of caspase 9 in XK469-induced apoptosis Z Ding et al involvement of the mitochondrial pathway in XK469-induced apoptosis. Since activated caspase 8 by the death receptor is able to cleave the pro-apoptotic Bcl2 family member Bid and then trigger a distinct apoptotic pathway involving the mitochondria in some cell types (Li et al., 1998; Luo et al., 1998) , it is possible that activation of caspase 9 in XK469-treated PA1 cells may be due to the activation of the death receptor-caspase 8-Bid-cytochrome c pathway. We have shown that cleavage of caspase 8 is not evident in XK469-treated cells (Figure 2a) . Therefore, it is unlikely that such activation of caspase 9 is triggered mainly by the caspase 8-Bid-cytochrome c pathway, although this possibility can not be excluded in other cell types. Thus, we conclude that XK469 induces apoptosis predominantly through the mitochondrial pathway. Members of the Bcl2 family play an important role in apoptosis by regulating the release of cytochrome c from the mitochondria to the cytosol (Gross et al., 1999) . It has been shown that anti-apoptotic members, such as Bcl-2 and Bcl-X L , inhibit cytochrome c release (Kluck et al., 1997; Yang et al., 1997) whereas the proapoptotic members, such as Bax, promote cytochrome c release, leading to the initiation of apoptosis (Korsmeyer, 1999) . Regulation of these members can occur through the post-translational modi®cation, including phosphorylation (Blagosklonny et al., 1999) and cleavage (Blagosklonny et al., 1996; Cheng et al., 1997; Gao and Dou, 2000) . Both can aect their subcellular localization and function (Gross et al., 1999) . It has also been shown that cleavage of Bcl2 by caspase 3 can convert the anti-apoptotic Bcl2 to a Baxlike proapoptotic molecule, thereby promoting apoptosis induction (Cheng et al., 1997) . In this study, we have clearly shown that Bcl2 is cleaved in XK469-treated PA1 cells (Figures 2c and 3b) , suggesting that cleavage of Bcl2 plays a role in releasing cytochrome c in XK469-induced apoptosis. Because cleavage of Bcl2 occurred at 24 h but not 12 h in XK469 treated cells (Figure 2d ), we believe that cleavage of Bcl2 is a secondary event. Since Bcl2 is cleaved by caspase 3 (Cheng et al., 1997) , it is likely that XK469 directly induces release of cytochrome c, leading to activation of caspase 9 and its downstream caspase 3, the latter is able to cleave Bcl2 to generate the Bax-like proapoptotic molecule, which can further promote cytochrome c release (Kirsch et al., 1999) . These results are in agreement with the two-stage model (Chen et al., 2000 (Chen et al., , 2001 in which the early release of cytochrome c is sucient to activate caspases while the late stage cytochrome c release serves as a positive feedback loop to ampli®cation of cytochrome c release (Chen et al., 2000 (Chen et al., , 2001 . It has been shown that cleavage of Bax and its subcellular localization play an important role in triggering cytochrome c release (Rosse et al., 1998) . Consistent with this notion, we have shown that Bax was cleaved upon XK469 treatment (Figures 2c and  3b ) and targeted to the mitochondria in XK469-treated cells (Figure 2e ). Since cleaved Bax is a more potent form of Bax capable of promoting cytochrome c release (Gao and Dou, 2000) , we believe that this cleaved Bax can also serve as another feedback loop to amplify apoptosis induction. Because overexpression of DN-casp 9 had no eect on XK469-induced cytochrome c release, although the activation of the mitochondrial caspase cascade and cleavage of Bcl2 and Bax were inhibited, we believe that cytochrome c release is not sucient for XK469-induced apoptosis. Unlike Bcl2 that is cleaved by caspase 3, Bax is cleaved Figure 4 Eects of DN-casp 9 overexpression on XK469-induced chemosensitivity and caspase 3 activation. (a) Overexpression of DN-casp 9 increases cells resistant to XK469. PA1 cells transfected with vector or DN-casp 9 were left untreated or treated with XK469 at 10, 20, 40 and 80 mg/ml for 2 days. The resulting cells were assessed for cell survival as described in Materials and methods (means+s.d., n=3). (b) Overexpression of DN-casp 9 inhibits XK469-induced caspase 3 activation. PA1 vector or DNcasp 9 expressing cells were left untreated or treated with XK469 at 10, 20, 40 and 80 mg/ml for 24 h. Caspase-3 activity was assayed as described in Materials and methods (means+s.d., n=3)
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The role of caspase 9 in XK469-induced apoptosis Z Ding et al by calpain (Gao and Dou, 2000) , the non-lysosomal calcium-activated neutral protease implicated in apoptosis (Wang, 2000) . Therefore, it is possible that XK469-induced apoptosis may also involve the activation of other proteases and this issue will need to be investigated. Taken together, our results suggest that XK469 is a potent inducer of apoptosis through multiple mechanisms to promote cytochrome c release, leading to activation of caspase 9 and induction of apoptosis.
We have shown that overexpression of DN-casp 9 inhibits XK469-induced caspase cascade and thus increases chemoresistance. This is consistent with the role of the mitochondrial pathway in XK469-mediated apoptosis, which may be part of its anticancer activity. Since PA1 cells expressing DN-casp 9 were not completely resistant to XK469-induced killing ( Figure  4a ), we believe that besides its ability to induce apoptosis via the mitochondrial pathway, XK469 may exert its apoptosis activity through other pathways such as calpain as discussed above. Given the fact that XK469 is able to inhibit topo II (Gao et al., 1999) and topo I activities (Snapka et al., 2001) , cause a G2/ M arrest of the cell cycle (Ding et al., 2001) , and induce apoptosis as shown in this study, the multiple mechanisms may begin to explain why XK469 demonstrates broad activity in preclinical tumor models.
In summary, we have found that XK469 can induce apoptosis of the human ovarian cancer PA1 cells. The induction of apoptosis by XK469 involves release of cytochrome c, activation of caspases 9, 7 and 3, and cleavage of PARP. Moreover, we showed that XK469 can cause cleavage of Bcl2 and Bax to promote cytochrome c release, thus accelerating apoptosis induction. Finally, we found that the blockade of caspase 9 activation inhibits XK469-induced caspase cascade and renders cells resistant to XK469-induced killing. Thus, our study de®nes another mechanism underlying XK469-induced anti-cancer activity and also provide the speci®c pathway by which XK469 induces apoptosis. Further experiments will focus on the mechanisms by which Bcl2 and Bax are cleaved by XK469 and cleaved Bcl2 and Bax promote cytochrome c release. In addition, the role of other proteases such as calpain in XK469-induced apoptosis will be addressed.
Materials and methods
Cell lines and culture conditions
The human ovarian cancer cell lines PA1 and SKOV3 were obtained from American Type Culture Collection and maintained in basal modi®ed Eagle's medium and McCoy's 5A medium, respectively. These cells were supplemented with 10% fetal bovine serum and antibiotics at 378C in a humidi®ed atmosphere consisting of 5% CO 2 and 95% air. Cells were grown in the presence of varying concentrations of XK469 for dierent intervals of time as indicated in the ®gure legends. Drugs R (+) XK469 (free acid, NSC698215) was obtained from the National Cancer Institute Drug Synthesis Branch (Bethesda, MD, USA) and dissolved in DMSO (Sigma). Final concentrations of DMSO in our experiments varied but did not exert any eects on working concentrations.
Generation of PA1 cells stably expressing dominant negative caspase 9 PA1 cells were transfected with a dominant negative caspase 9 expression plasmid, as well as an empty vector as a control as described previously (Wu and Ding, 2002) . Individual clones were isolated after selection with G418 (500 mg/ml) (GIBCO/BRL, Gaithersburg, MD, USA). Transfectants were maintained in the presence of G418 (500 mg/ml). Clone #8 was used in this study because this clone has been shown to block etoposide-induced apoptosis (Wu and Ding, 2002) .
Cell growth inhibition
Cells were plated at a density of 5000/well (in triplicate) in 96-well plates and treated with dierent concentrations of XK469. After 24 or 48 h treatment, cells were stained with crystal violet. The stained cells were ®xed with 10% acetic acid followed by measurement of OD at 600 nm. Cell survival was calculated as described ).
Analysis of apoptosis
Apoptotic cells were detected by morphological changes using DAPI staining and DNA fragmentation assay as described previously (Wu et al., 1999; Wu and El-Deiry, 1996) . For morphological changes, cells treated with or without XK469 (60 mg/ml) for 24 h were harvested and resuspended in PBS containing DAPI. Cell morphology was evaluated bȳ uorescent microscopy, and apoptotic cells were identi®ed by the appearance of cell shrinkage, nuclear condensation, and/or the appearance of fragmented nuclei. For the DNA fragmentation assay, cells treated with or without XK469 for 24 h were lysed in 1 ml of lysis buer containing 5 mM TrisHCl (pH 7.4), 5 mM EDTA, and 0.5% Triton X-100 at 378C for 30 min. The lysate was treated with proteinase K (200 mg/ml) at 508C for 1 h, extracted with phenol/chloroform, precipitated with ethanol, and treated with RNase A (1 mg/ml) at 508C for 1 h. DNA integrity was assessed following agarose gel (1.5%) electrophoresis and ethidium bromide staining.
Assay of caspase 3 activity
The enzymatic activity of caspase 3 was assayed using the caspase-3 colorimetric assay kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. Brie¯y, cells treated with 0, 10, 20, 40, and 80 mg/ml of XK469 for 24 h were lysed in lysis buer for 10 min on ice. The lysed cells were centrifuged at 14 000 r.p.m. for 5 min, and 150 mg protein was incubated with 50 ml of reaction buer and 5 ml of caspase 3 at 378C for 1 h, and the absorbance was measured at a substrate wavelength of 405 nm on a plate reader.
Measurement of cytochrome c release
Cells were plated onto 75-cm¯asks one day before treatment. Following treatment with 0, 40 and 80 mg/ml of XK469 for
The role of caspase 9 in XK469-induced apoptosis Z Ding et al 24 h, both¯oating and attached cells were harvested and cytosolic cytochrome c was extracted as described . Brie¯y, harvested cells were resuspended in ice-cold lysis buer (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 20 ml protease inhibitors (Sigma, MO, USA), 4 mM dithiothreitol containing 250 mM sucrose, and incubated for 1 h at 48C. The lysates were passed through a 26 gauge syringe 15 times and then centrifuged at 10 000 r.p.m. at 48C for 20 min. The resulting supernatant was analysed by immunoblot analysis using anti-cytochrome c antibody (ZYMED Laboratories Inc, CA, USA) as described below.
Isolation of mitochondria
Mitochondria were isolated as described by Juin et al. (1999) with minor modi®cations. Brie¯y, cells treated with or without XK469 (80 mg/ml) for 24 h were harvested and resuspended in lysis buer (250 mM sucrose, 10 mM HEPES-KOH, pH 7.5, 50 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT and protease inhibitors (Sigma, MO, USA), and incubated for 30 min at 48C. After homogenization for 20 strokes with a Dounce homogenizer, cell lysates were centrifuged twice at 750 g for 10 min at 48C. The supernatant was centrifuged at 13 000 g to pellet mitochondria-enriched fraction. Protein concentrations were determined by the Protein Assay Kit (Bio-Rad, Hercules, CA, USA).
Western blot analysis
Whole cell lysates from both attached and¯oating cells were prepared as described ) and protein concentration was determined using the Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Total cellular proteins (50 mg) were electrophoresed through 8 ± 15% denaturing polyacrylamide gels and transferred to a nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, NH, USA) by electroblotting. The blots were probed or reprobed with the antibodies, and bound antibody was detected using Enhanced Chemiluminescence Reagent (Amersham Pharmacia, Piscataway, NJ, USA) according to the manufacturer's protocol. Mouse monoclonal anti-caspase-7 (clone B94-1) antibody, rabbit polyclonal anti-bax (13666E) were purchased from PharMingen (San Diego, CA, USA). Goat polyclonal anti-caspase-8 (C-20) antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit polyclonal anti-caspase-9 antibody and rabbit polyclonal anti-PARP was purchased from New England Biolabs, Inc.
(Beverly, MA, USA). Anti-cytochrome oxidase subunit IV (COX IV) was purchased from Molecular Probes (Eugene, OR, USA). Mouse anti-caspase-3 (Ab1), mouse monoclonal anti-Bcl-X L (Ab2), mouse monoclonal anti-Bcl2 (Ab1) and anti-actin antibodies were purchased from Calbiochem (Boston, MA, USA).
